Regulations
US FDA aims to clarify reporting rules for biologics CMC changes
RegulationsUS FDA aims to clarify reporting rules for biologics CMC changesUS FDA aims to clarify reporting rules for biologics CMC changes
Biologic drug makers that tweak manufacturing processes after approval have a better idea of when and how to inform the FDA of the changes.